Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer

被引：25

作者：

Eichholz, Andrew ^{[1
]}

Ferraldeschi, Roberta ^{[1
]}

Attard, Gerhardt ^{[1
]}

de Bono, Johann S. ^{[1
]}

机构：

[1] Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England

来源：

MOLECULAR AND CELLULAR ENDOCRINOLOGY | 2012年 / 360卷 / 1-2期

关键词：

Abiraterone; Orteronel (TAK-700); VN/124-1 (TOK-001); MDV3100; Heat shock proteins; OGX-427; ABIRATERONE ACETATE; ANTIANDROGEN WITHDRAWAL; PROTEIN EXPRESSION; ANTITUMOR-ACTIVITY; PLUS PREDNISONE; INHIBITOR; GENE; DOCETAXEL; THERAPY; TRIAL;

D O I：

10.1016/j.mce.2011.09.038

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Patients with advanced prostate cancer initially respond very well to medical or surgical castration. Despite a good initial response, the disease progresses to a castration-resistant state. Castration-resistant prostate cancer (CRPC) remains addicted to androgen receptor signaling. The addition of conventional anti-androgen agents, such as bicalutamide, only provides a transient benefit. This has led to a search for further drug targets. Cytochrome P450 17 (CYP17) is an enzyme that is vital for the adrenal biosynthesis of androgens. The CYP17 inhibitor abiraterone acetate has a proven benefit in a phase III randomized trial and other CYP17 inhibitors are currently being evaluated. The novel antiandrogen MDV3100 is a small molecule androgen receptor antagonist with promising activity. Heat shock proteins (HSPs) bind to the androgen receptor and modify its activity. Several HSP inhibitors are under evaluation in clinical trials. This review explores the role of CYP17 inhibitors, MDV3100, and HSP inhibitors. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：68 / 75

页数：8

共 69 条

[1] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[2] Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Swermenhuis, Joost F. ;

Olmos, David ;

Reid, Alison H. M. ;

Vickers, Elaine ;

A'Hern, Roger ;

Levink, Rianne ;

Coumans, Frank ;

Moreira, Joana ;

Riisnaes, Ruth ;

Oommen, Nikhil Babu ;

Hawche, George ;

Jameson, Charles ;

Thompson, Emilda ;

Sipkema, Ronald ;

Carden, Craig P. ;

Parker, Christopher ;

Dearnaley, David ;

Kaye, Stan B. ;

Cooper, Colin S. ;

Molina, Arturo ;

Cox, Michael E. ;

Terstappen, Leon W. M. M. ;

de Bono, Johann S. .

CANCER RESEARCH, 2009, 69 (07) :2912-2918

[3] PHARMACOLOGY OF NOVEL STEROIDAL INHIBITORS OF CYTOCHROME P450(17-ALPHA) (17-ALPHA-HYDROXYLASE C17-20 LYASE) [J].

BARRIE, SE ;

POTTER, GA ;

GODDARD, PM ;

HAYNES, BP ;

DOWSETT, M ;

JARMAN, M .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1994, 50 (5-6) :267-273

[4] Pleiotropic Functional Properties of Androgen Receptor Mutants in Prostate Cancer [J].

Bergerat, Jean-Pierre ;

Ceraline, Jocelyn .

HUMAN MUTATION, 2009, 30 (02) :145-157

[5] Molecular determinants of resistance to antiandrogen therapy [J].

Chen, CD ;

Welsbie, DS ;

Tran, C ;

Baek, SH ;

Chen, R ;

Vessella, R ;

Rosenfeld, MG ;

Sawyers, CL .

NATURE MEDICINE, 2004, 10 (01) :33-39

[6]

Dalesio O, 2000, LANCET, V355, P1491

[7] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [J].

Danila, Daniel C. ;

Morris, Michael J. ;

de Bono, Johann S. ;

Ryan, Charles J. ;

Denmeade, Samuel R. ;

Smith, Matthew R. ;

Taplin, Mary-Ellen ;

Bubley, Glenn J. ;

Kheoh, Thian ;

Haqq, Christopher ;

Molina, Arturo ;

Anand, Aseem ;

Koscuiszka, Michael ;

Larson, Steve M. ;

Schwartz, Lawrence H. ;

Fleisher, Martin ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1496-1501

[8] Drugging the heat shock factor 1 pathway Exploitation of the critical cancer cell dependence on the guardian of the proteome [J].

de Billy, Emmanuel ;

Powers, Marissa V. ;

Smith, Jennifer R. ;

Workman, Paul .

CELL CYCLE, 2009, 8 (23) :3806-3808

[9]

de Bono JS, 2010, ANN ONCOL, V21, P3

[10] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

← 1 2 3 4 5 6 7 →